OCT 29, 2020 8:00 AM PDT

Cell types to targets: Single cell RNA-sequencing for drug discovery

Sponsored by: 10x Genomics

Event Date & Time
Date:  October 29, 2020
Time: 8:00am (PDT),  11:00am (EDT),  4:00pm (CET)
What cell types cause and perpetuate disease? For many diseases, scientists only have guesses to this critical question. Single cell RNA-sequencing (scRNA-seq) presents a new opportunity to survey the full range of cells in a tissue and dissect how individual cell types change in their expression profiles, abundance, and interactions in the disease context. scRNA-seq can also reveal unexpected new subtypes or functional states related to disease.
In this webinar, Dr. Sarah Middleton, Computational Biologist at GlaxoSmithKline, will discuss how taking a cell type–first approach to understanding disease can be a powerful strategy to inform multiple steps of the drug discovery pipeline, from target identification to patient stratification. A key requirement for success of this strategy is accurate and deep cell-type classification, which remains challenging, especially for subtypes. Dr. Middleton will discuss how to alleviate these challenges both through computational approaches and integration of multiomic data types. Finally, she will discuss what is needed to scale up these approaches and make full use of the huge compendiums of single cell data now becoming available.
Learning Objectives
  • How scRNA-seq can be used in drug discovery and development
  • The challenges of cell subtype identification and how to address them with computational tools and multiomic data integration
  • The importance of automated analysis methods and pipelines, and pitfalls to avoid
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

You May Also Like
Loading Comments...
  • See More